Human variability in glucuronidation in relation to uncertainty factors for risk assessment

Food and Chemical Toxicology

Volumn 39, Issue 12, 2001, Pages 1153-1173

  Dorne, J L C M ^a   Walton, K ^a   Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Glucuronidation; Human variability; Pharmacokinetics; Risk assessment; Sensitive subgroups; Uncertainty factors

Indexed keywords

CARPROFEN; CHLORAMPHENICOL; CLOFIBRIC ACID; DIFLUNISAL; KETOPROFEN; LAMOTRIGINE; LORAZEPAM; LORMETAZEPAM; MORPHINE; NALMEFENE; OXAZEPAM; PARACETAMOL; PROPRANOLOL; ZIDOVUDINE; ZILEUTON; ZOMEPIRAC;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; GLUCURONIDATION; HUMAN; KINETICS; METABOLIC CLEARANCE RATE; NEWBORN; NORMAL HUMAN; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCURONIDES; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; LIVER DISEASES; MALE; MEDLINE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MINORITY GROUPS; SUBSTRATE SPECIFICITY;

EID: 0034756279     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(01)00087-4     Document Type: Article

References (192)

1. Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam
2. Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives
3. The effect of chloroquine on paracetamol disposition and kinetics
4. Pharmacokinetics of ketoprofen in the elderly
5. Pharmacokinetics of oxazepam in healthy volunteers
6. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver
7. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children
8. Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate
9. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers
10. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton
11. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis
12. The effect of food on zileuton pharmacokinetics
13. Age and the pharmacokinetics of morphine
14. The effect of food on the systemic availability of ketoprofen
15. The effect of propranolol on paracetamol metabolism in man
16. 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)
17. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance
18. Influence de l'age et du sexe sur la pharmacocinetique du paracetamol
19. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases
20. Pharmacocinetique du clofibrate chez le nouveau-ne a terme icterique
21. The pharmacokinetics of zileuton in healthy young and elderly volunteers
22. The rate of acetaminophen metabolism in the elderly and the young
23. Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children
24. Temporal variations of lorazepam pharmacokinetics
25. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
26. Chloramphenicol dosage and pharmacokinetics in infants and children
27. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function
28. Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: A pharmacokinetic analysis
29. Morphine pharmacokinetics in renal failure
30. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates
31. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs
32. Studies on the substrate specificity of human intestinal UDP- Glucuronosyltransferases 1A8 and 1A10
33. Canadian multicenter azidothymidine trial: AZT pharmacokinetics
34. Morphine metabolism in children
35. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man
36. Human UGT2B7 catalyzes morphine glucuronidation
37. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans
38. Metabolism of 14C-acetaminophen in humans and laboratory animals
39. Pharmacokinetic properties of carprofen in humans
40. Age-related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine
41. Hepatic extraction of morphine is impaired in cirrhosis
42. Patient-controlled analgesic therapy, Part IV: Pharmacokinetics and analgesic plasma concentrations of morphine
43. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease
44. Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion
45. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine
46. Glucuronidation in humans. Pharmacogenetic and developmental aspects
47. Diflunisal and its conjugates in patients with renal failure
48. Nalmefene: Intravenous safety and kinetics of a new opioid antagonist
49. Pharmacokinetics of lormetazepam after cimetidine
50. Uncertainty factors for chemical risk assessment: Human variability in the pharmacokinetics of CYP1A2 probe substrates
51. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus
52. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man
53. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal
54. Pharmacokinetics of lamotrigine in patients with renal impairment: Influence of haemodialysis
55. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease
56. Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses
57. Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses
58. Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: Influence of probenecid
59. Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys
60. Loss of analgesic effect of morphine due to coadministration of rifampin
61. Effects of liver disease on the disposition of the opioid antagonist nalmefene
62. The influence of age on the pharmacokinetics of paracetamol
63. Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients
64. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection
65. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins
66. Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography. Use in pharmacokinetic studies of lorazepam
67. Lorazepam kinetics in the elderly
68. Oxazepam kinetics: Effects of age and sex
69. Interaction of cimetidine with oxazepam, lorazepam, & flurazepam
70. Comparative single-dose kinetics and dynamics of lorazepan, alprazalan prazepan and placebo
71. Kinetic and dynamic study of intravenous lorazepam: Comparison with intravenous diazepam
72. Cognitive effects of beta-adrenergic antagonists after single doses: Pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo
73. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis
74. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations
75. Human variability in susceptibility to toxic chemicals - A preliminary analysis of pharmacokinetic data from normal individuals
76. Risk evaluation: Criteria arising from legal traditions and experience with quantitative risk assessment in the United States
77. Disposition of lorazepam in human beings: Enterohepatic recirculation and first-pass effect
78. Retigabine N-glucuronidation and its potential role in enterohepatic circulation
79. The influence of liver dysfunction on the pharmacokinetics of carprofen
80. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers
81. Urinary pharmacokinetics of orally administered ketoprofen in man
82. Kinetics and biotransformation of lormetazepam II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: First-pass effect
83. Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration
84. International programme on chemical safety: Assessing human health risks of chemicals: Derivation of guidance values for health-based exposure limits
85. International programme on chemical safety: Principles for the assessment of risk to human health from exposure to chemicals
86. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs
87. Paracetamol elimination in patients with non-insulin dependent diabetes mellitus
88. Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children
89. Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam
90. Effects of aging and liver disease on the disposition of lorazepam
91. Determination of ketoprofen by high-performance liquid chromatography from serum and urine: Clinical application in children with juvenile rheumatoid arthritis
92. 458): A UDP-glucuronosyltransferase encoded by a polymorphic gene
93. Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: Single dose studies
94. Variability of human hepatic UDP-glucuronosyltransferase activity
95. Morphine pharmacokinetics in early infancy
96. Pharmacokinetics of lorazepam in critically ill neonates with seizures
97. Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis
98. Uncertainty and variability in human exposures to soil contaminants through home-grown food: A Monte Carlo assessment
99. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes
100. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects
101. Extrahepatic metabolism of morphine occurs in humans
102. Disposition of four drugs in malnourished children
103. Bioavailability of oxazepam: Absence of influence of food intake
104. Morphine pharmacokinetics in premature and mature newborn infants
105. Clofibrate pharmacokinetics in chronic renal-failure
106. Influence of sex and oral contraceptive steroids on paracetamol metabolism
107. Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminopen's metabolic pathways
108. Paracetamol metabolism in pregnant women
109. Comparison of paracetamol metabolism in young adult and elderly males
110. Drug glucuronidation in humans
111. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug
112. Age difference in kinetics of diazepam and lorazepam in man
113. Cimetidine does not alter morphine disposition in man
114. Sensitive and specific morphine radioimmunoassay with iodine label: Pharmacokinetics of morphine in man after intravenous administration
115. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease
116. Effect of renal impairment and hemodialysis on lorazepam kinetics
117. Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection
118. Kinetics of acetaminophen (Ac) following single strength (SS-Ac) vs double strength (DS-Ac) administration to febrile children
119. Comparative bioavailability and pharmacokinetics of chloramphenicol after intravenous chloramphenicol succinate in premature infants and older patients
120. Acetaminophen accumulation in pediatric patients after repeated therapeutic doses
121. Variation in morphine pharmacokinetics in children with cancer
122. Pharmacokinetic study of chloramphenicol in patients with liver disease
123. Zomepirac kinetics in healthy males
124. Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals
125. Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans
126. Disposition of zomepirac sodium in man
127. Interethnic differences in drug glucuronidation: A comparison of paracetamol metabolism in Caucasians and Chinese
128. The pharmacokinetics of morphine and morphine glucuronides in kidney failure
129. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam
130. S-Oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7
131. Normal metabolism of morphine in cirrhosis
132. Pharmacocinetique de la zidovudine (AZT) et de son metabolite (G.AZT) chez le sujet sain et l'insuffisant renal
133. Age-related morphine kinetics in infants
134. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome)
135. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure
136. A method for the determination of UDP-glucuronosyltransferase activity toward aryl-carboxylic acids
137. Chronokinetics of ketoprofen administered orally and by continuous intravenous infusion
138. Structural and functional studies of UDP-glucuronosyltransferases
139. Chloramphenicol pharmacokinetics in the newborn
140. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers
141. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration
142. The pharmacokinetics and metabolism of 14C-carprofen in man
143. Pharmacokinetics of carprofen in plasma and synovial fluid
144. Lorazepam pharmacodynamics and pharmacokinetics in children
145. Data-derived safety factors for the evaluation of food additives and environmental contaminants
146. Human variability and non cancer risk assessment - An analysis of the default uncertainty factor
147. Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers
148. Effects of posture and sleep on the pharmacokinetics of paracetamol (acetaminophen) and its metabolites
149. Interactions and comparative effects of zopiclone, diazepam and lorazepam on psychomotor performance and on elimination pharmacokinetics in healthy volunteers
150. Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: Identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7
151. Chloramphenicol pharmacokinetics in infants and young children
152. Kinetics of morphine in patients with renal failure
153. Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone
154. Morphine pharmacokinetics and pain assessment in premature neonates
155. Studies on morphine disposition: Influence of general anaesthesia on plasma concentrations of morphine and its metabolites
156. Studies on morphine disposition: Influence of renal failure on the kinetics of morphine and its metabolites
157. Establishing data-derived uncertainty factors from published pharmaceutical clinical trial data
158. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients
159. Bioavailability and pharmacokinetics of oxazepam
160. Racial differences in propranolol enatiomer kinetics following simultaneous iv and oral administration
161. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine
162. Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol
163. The use of kinetic and dynamic data in risk assessment of drugs
164. Pharmacokinetics of zidovudine in patients with liver cirrhosis
165. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide
166. Metabolism of thiamphenicol and comparative studies of its urinary and biliary excretion with chloramphenicol in various species
167. The influence of diflunisal on the pharmacokinetics of oxazepam
168. Pharmacokinetics of intravenous morphine in balanced anesthesia: Studies in children
169. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children
170. Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency
171. The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man
172. Disposition of acetaminophen in normal, alcoholic and cirrhotic subjects
173. Partial metabolic clearances as determinants of the oral bioavailability of propranolol
174. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women
175. Uncertainty factors for chemical risk assessment: Interspecies differences in the in vivo pharmacokinetics and metabolism of CYP1A2 substrates
176. Uncertainty factors for chemical risk assessment: Interspecies differences in glucronidation
177. Morphine disposition in cirrhosis
178. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers
179. Principles for the assessment of risk to human health from exposure to chemicals
180. Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children
181. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver
182. Influence of renal function on the elimination of morphine and morphine glucuronides
183. The pharmacokinetics of single oral doses of zileuton 200 to 800 mg, its enantiomers, and its metabolites, in normal healthy volunteers
184. Renal failure does not impair the metabolism of morphine
185. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers
186. The metabolism of zomepirac sodium. II. [Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man]
187. The association of age and frailty with paracetamol conjugation in man
188. Interindividual and interethnic differences in the demethylation and the glucuronidation of codeine
189. Lamotrigine pharmacokinetics: Oral and iv infusion in man
190. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites
191. Comparative pharmacokinetics of zidovudine and its toxic catabolite 3′-amino-3′-deoxythymidine in HIV-infected patients